Breaking News

Wyeth Buys Mochida Pain Drug

Wyeth has entered an agreement to purchase the global rights to develop and market an experimental pain medication from Mochida Pharmaceutical Co. Ltd., the Japanese company said on Wednesday. Financial terms were not disclosed.

The drug candidate, a new class of pain medications called TRPV1 antagonists, is in preclinical trials and is being developed to treat severe pain. Mochida will receive a one-time payment from Wyeth, as well as success-based development milestone payments. Mochida will retain the option of jointly developing and marketing the drug with Wyeth in Japan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters